LVTX LAVA Therapeutics NV
1,057
$3.00
$0.16
(5.63%)
| Watchers | 1,057 |
| 52-Wk Low | $1.13 |
| 52-Wk High | $6.47 |
| Market Cap | $74.66M |
| Volume | 103,908.00 |
| 52-Wk High | $6.47 |
| 52-Wk Low | $1.13 |
LAVA Therapeutics GAAP EPS of -$0.24 beats by $0.18SeekingAlpha.com: All News • about 2 months ago
LAVA Therapeutics GAAP EPS of -$0.24 beats by $0.18...
Share to Feed
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2...
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX...
LAVA Therapeutics (NASDAQ:LVTX Get Free Report)s share price was up 37.7% during trading on Monday . The company traded as high as $3.72 and last traded at $3.03. Approximately...
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this...
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the...